In crowded Kinshasa, the capital of the Democratic Republic of Congo, two strains of mpox are sweeping through a community that relies on selling sex, threatening global efforts to contain the virus, The New York Times’ Stephanie Nolen reports. Hundreds of thousands of vaccines sent to the country have not been used, according to the report. The detection of a new, fast-spreading strain of the virus in a remote mining town in eastern Congo led the World Health Organization to declare mpox a global public health emergency in August, and the spread has only accelerated since then. TheFly notes that Geovax (GOVX) and Emergent Biosolutions (EBS) both have mpox-related products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX:
- GeoVax Labs receives Notice of Allowance for cancer vaccine patent
- WHO determines mpox upsurge still constitutes public health emergency
- GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology
- GeoVax Labs Reports Improved Earnings and Strategic Progress
- GeoVax Labs reports Q3 EPS (91c), consensus ($1.48)